The North America NGS-based RNA-sequencing market is expected to exhibit steady revenue growth from 2020 through 2035, underpinned by rapid technology adoption, expanding clinical applications, and increasing R&D spending. In 2025, total market revenue is projected to reach approximately 1,350 Million USD, with a sustained annual growth rate driven by advancements in sequencing technologies, integration of automation, and higher throughput capabilities. The market is forecast to surpass 3,540 Million USD by 2035 as genetic and transcriptomic profiling become routine in both academic and clinical environments.
Read More - https://bussinessinsights.com/research-report/north-america-ngs-based-rna-sequencing-market
Diagnostics is poised to be the leading application for NGS-based RNA-sequencing in North America by 2025, as hospitals and clinical labs increasingly incorporate transcriptomic data into oncology and rare disease diagnosis. Closely behind, drug discovery is leveraging RNA-seq for target identification and safety assessments, while biomarker discovery continues to gain momentum with a surge in translational research programs. This broadening adoption across healthcare and pharmaceutical research is expected to drive continued growth and innovation throughout the forecast period.
Request Free Sample- https://bussinessinsights.com/request/healthcare/north-america-ngs-based-rna-sequencing-market
Who are the key players in North America NGS-based RNA-sequencing Market industry?
The top 5 players are Illumina, Thermo Fisher Scientific, Agilent Technologies, QIAGEN, and PerkinElmer. These companies drive innovation through advanced sequencing platforms, sample preparation solutions, and comprehensive bioinformatics. Their extensive product portfolios, strong distribution networks, and continuous investments in R&D significantly influence the North American RNA-sequencing landscape.
What is the North America NGS-based RNA-sequencing Market growth?
The North America NGS-based RNA-sequencing market has experienced robust growth, primarily driven by rising R&D activities and adoption in clinical diagnostics. For example, Illumina reported double-digit revenue growth in 2023, fueled by expanding applications in transcriptomics, personalized medicine, and biomarker discovery among research and healthcare institutions.
Which segment accounted for the largest North America NGS-based RNA-sequencing Market share?
In 2023, the research and academic institutes segment held the largest market share, owing to increased government funding and large-scale genomic studies. These organizations utilize NGS-based RNA sequencing for basic research, disease characterization, and biomarker discovery, driving significant adoption across projects and collaborations.
Thanks & Regards,
Manisha C
sales [at] bussinessinsights.com